Aventis Groupe: Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
Dupixent® (dupilumab)applicationfor treatment ofchronic spontaneous urticaria (CSU) inadults and adolescents accepted for FDA review More than 300,000 people in the U.S. suffer from CSU that […]